SEC Form 4 · accession 0001628280-16-012503
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Haluska
Officer — SVP, Clinical R&D, CMO
Period of report
Mar 7, 2016
Accepted (ET)
Mar 9, 2016 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $6.51 | Mar 7, 2016 | A | 60,000 | A | — | — | Common Stock | 60,000 | 60,000 | D |
| Restricted Stock UnitsF3,F4 | $0.00 | Mar 7, 2016 | A | 18,000 | A | — | — | Common Stock | 18,000 | 18,000 | D |
Explanation of responses
- F1Options vest 25% per year on the anniversary of the grant
- F2Options expire 10 years from grant date
- F3Restricted Stock Units vest as to 33-1/3% per year on the anniversary of the grant
- F4N/A